| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Aiming at a clinically effective gene-modified T-cell based adoptive immunotherapy against human leukemias, we multilaterally studied the leukemia reactive T-cell network comprising leukemia stem cell reactive T-cell receptor (TCR) gene modified CD8 killer T cells and CD4 helper T cells, targeting Wilms Tumor 1 (WT1) and Aurora Kinase A (AURKA).This study included a unique HLA class I restricted TCR gene-modified CD4 T cells and autologous transplantation using WT1-specific TCR gene-modified hematopoietic stem cells. In parallel, we conducted a clinical trial.
Additionally, we also have developed a novel chimeric antigen receptor (CAR) gene-modified T cells, expressing affinity-increased CD16 which can employ anticancer monoclonal antibodies for target recognition, e.g., mogamulizumab against adult T cell leukemia. Furthermore, we are now developing a novel CAR gene which can recognize an epitope/HLA complex derived from cytoplasmic cancer antigens like as TCR-T cells.
|
